Early vs. late MRD response- and risk-based treatment intensification of childhood acute lymphoblastic leukemia: a prospective pilot study from Saudi Arabia

Table 2 Treatment assignment and response assessment, B cell ALL (n = 196)

Variable	Value	Count	%
Induction arm^a	A	125	63.8
	B	50	25.5
	C	21	10.7
Day 15 BM morphology	M1	182	92.9
	M2	8	4.1
	M3	5	2.6
	Missing	1	0.5
Day 15 BM MRD (%)	< 0.01	84	42.9
	≥ 0.01	50	25.5
	Not available	62	31.6
Day 29 BM morphology	M1	191	97.4
	M2	1	0.5
	M3	2	1.0
	Not available	2	1.0
Day 29 BM MRD (%)	< 0.01 (negative)	177	90.3
	≥ 0.01 (positive)	13	6.6
	Not determined	6	3.1
Post induction arm^b	A	114	58.2
	B	38	19.4
	C	40	20.4
	Not applicable	4	2.0

^aPatients with Philadelphia translocation positive were excluded from the analysis (n = 4)
^b4 patients were not eligible for post-induction analysis and were reported as “Not applicable”. Post-induction Arms C and C + HDMTX were combined

ISSN: 2162-3619